Centers for Medicare & Medicaid Services (CMS) will begin negotiating with manufacturers on the price of Medicare Part D drugs beginning this year. In September, CMS will publish the list of 10 Part D selected drugs for negotiations. A key issue in the negotiations will be determination of the fair market price for a product.

ICON panelists will bring their perspectives on critical issues around support for a product’s fair market price.


Key discussion topics

  • Outline how CMS might select the 10 products that will be required to negotiate their prices this fall
  • Describe how CMS will determine fair market prices for Medicare Part D drugs
  • Suggest actions that manufacturers could take in response to the Medicare Part D price negotiation requirements


Mark McCoy

Director Client Engagement, ICON Pricing, Market Access & Reimbursement

ICON panelists:

Earlene Biggs

Divisional Principal, Market Access

Bruce Capobianco

Senior Director, Real World Evidence

Tanja Obradovic

VP, Scientific Affairs, Oncology Medical Strategy

Ki Park

VP Patient Insight, Market Access & Commercial

Nancy Risebrough

Senior Principal, Global HEOR


This webinar will benefit pharmaceutical and biotech professionals in the following areas:

  • Channel Marketing
  • Clinical
  • Competitive Intelligence
  • Government Affairs
  • Health Economics and Outcomes Research
  • Market Access
  • Marketing
  • Managed Markets
  • Market Research
  • Real World Evidence
  • Regulatory Affairs